Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

KRAS is mutated in approximately 25% of cancer patients and first KRAS G12C-specific inhibitors showed promising responses. Pancreatic cancer has the highest frequency of KRAS mutations but the prevailing KRAS G12D mutation is difficult to target. Inhibition of the GTP exchange factor (GEF) SOS1—KRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Plangger, Adelina, Rath, Barbara, Stickler, Sandra, Hochmair, Maximilian, Lang, Clemens, Weigl, Lukas, Funovics, Martin, Hamilton, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437170/
https://www.ncbi.nlm.nih.gov/pubmed/36048281
http://dx.doi.org/10.1007/s12672-022-00550-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437170/
https://www.ncbi.nlm.nih.gov/pubmed/36048281
http://dx.doi.org/10.1007/s12672-022-00550-w

Ejemplares similares